​

Cadrenal Therapeutics Stock (NASDAQ:CVKD)

OwnershipFinancialsChart
Cadrenal Therapeutics by TradingView

Previous Close

$1.51

52W Range

$1.28 - $14.64

50D Avg

$2.23

200D Avg

$5.63

Market Cap

$4.74M

Avg Vol (3M)

$425.99K

Beta

1.86

Div Yield

-

CVKD Company Profile

Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

Jan 20, 2023

Website

CVKD Performance

CVKD Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-13.46M$-10.96M$-7.63M
Net Income-$-10.65M$-8.36M
EBITDA$-13.46M$-10.65M$-8.34M
Basic EPS$-6.64$-8.73$-9.63
Diluted EPS$-6.64$-8.73$-9.63

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
XCURExicure, Inc.
IBIOiBio, Inc.
TAOXTAO Synergies Inc.
RLYBRallybio Corporation
KLTOKlotho Neurosciences, Inc.
CLGNCollPlant Biotechnologies Ltd.
NRSNNeuroSense Therapeutics Ltd.
SONNSonnet BioTherapeutics Holdings, Inc.